ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 237 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2022. The put-call ratio across all filers is 2.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,143,246 | -18.7% | 396,725 | +5.2% | 0.00% | -20.0% |
| Q2 2023 | $17,401,989 | +17.0% | 377,238 | +1.7% | 0.01% | 0.0% |
| Q1 2023 | $14,875,576 | -13.8% | 370,962 | -0.4% | 0.01% | -16.7% |
| Q4 2022 | $17,247,454 | +14.1% | 372,274 | +2.0% | 0.01% | +20.0% |
| Q3 2022 | $15,120,000 | -54.0% | 365,106 | -33.8% | 0.01% | -54.5% |
| Q2 2022 | $32,881,000 | -16.3% | 551,126 | +1.9% | 0.01% | -8.3% |
| Q1 2022 | $39,269,000 | -11.3% | 540,744 | +2.8% | 0.01% | -7.7% |
| Q4 2021 | $44,247,000 | -4.5% | 526,183 | +2.4% | 0.01% | -13.3% |
| Q3 2021 | $46,345,000 | -2.2% | 513,849 | +3.4% | 0.02% | -6.2% |
| Q2 2021 | $47,399,000 | -30.6% | 497,101 | -17.1% | 0.02% | -36.0% |
| Q1 2021 | $68,252,000 | -9.2% | 599,431 | +10.3% | 0.02% | -16.7% |
| Q4 2020 | $75,206,000 | +85.9% | 543,274 | +10.4% | 0.03% | +57.9% |
| Q3 2020 | $40,454,000 | +38.0% | 492,194 | +31.3% | 0.02% | +35.7% |
| Q2 2020 | $29,317,000 | +92.3% | 374,792 | +9.2% | 0.01% | +55.6% |
| Q1 2020 | $15,244,000 | +6.4% | 343,099 | +2.2% | 0.01% | +12.5% |
| Q4 2019 | $14,333,000 | +1.6% | 335,579 | +1.8% | 0.01% | 0.0% |
| Q3 2019 | $14,105,000 | -30.2% | 329,693 | +3.5% | 0.01% | -33.3% |
| Q2 2019 | $20,220,000 | -3.2% | 318,418 | +5.8% | 0.01% | -7.7% |
| Q1 2019 | $20,878,000 | +83.5% | 301,003 | +15.1% | 0.01% | +44.4% |
| Q4 2018 | $11,375,000 | -42.3% | 261,611 | +1.3% | 0.01% | -30.8% |
| Q3 2018 | $19,717,000 | +4.8% | 258,277 | +5.5% | 0.01% | -7.1% |
| Q2 2018 | $18,812,000 | +65.3% | 244,720 | +9.7% | 0.01% | +55.6% |
| Q1 2018 | $11,379,000 | +42.2% | 223,154 | +29.3% | 0.01% | +50.0% |
| Q4 2017 | $8,003,000 | -17.2% | 172,539 | -4.9% | 0.01% | -25.0% |
| Q3 2017 | $9,666,000 | -29.1% | 181,470 | -17.3% | 0.01% | -38.5% |
| Q2 2017 | $13,628,000 | -5.1% | 219,415 | +3.6% | 0.01% | -7.1% |
| Q1 2017 | $14,356,000 | +2.7% | 211,797 | +6.5% | 0.01% | -6.7% |
| Q4 2016 | $13,980,000 | +6.9% | 198,821 | +7.8% | 0.02% | 0.0% |
| Q3 2016 | $13,083,000 | +56.6% | 184,412 | +8.0% | 0.02% | +50.0% |
| Q2 2016 | $8,355,000 | -21.8% | 170,806 | +1.2% | 0.01% | -28.6% |
| Q1 2016 | $10,683,000 | -38.1% | 168,735 | +9.7% | 0.01% | -39.1% |
| Q4 2015 | $17,252,000 | +25.9% | 153,788 | +8.1% | 0.02% | +15.0% |
| Q3 2015 | $13,705,000 | +44.4% | 142,291 | +53.6% | 0.02% | +53.8% |
| Q2 2015 | $9,488,000 | +188.7% | 92,657 | +75.1% | 0.01% | +160.0% |
| Q1 2015 | $3,287,000 | +79.8% | 52,928 | +27.1% | 0.01% | +66.7% |
| Q4 2014 | $1,828,000 | -17.8% | 41,644 | +6.1% | 0.00% | -25.0% |
| Q3 2014 | $2,223,000 | +233.8% | 39,268 | +164.8% | 0.00% | +300.0% |
| Q2 2014 | $666,000 | +170.7% | 14,828 | +195.1% | 0.00% | – |
| Q1 2014 | $246,000 | – | 5,024 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |